Four key factors can greatly impact how much weight people lose while taking GLP-1 drugs like Ozempic, Wegovy, Victoza, and Saxenda. Here's what to know.

Injectable weight loss drugs are popular right now but can be hard to get because they are in short supply or too expensive without insurance. The result is that some people are skipping the doctor's office and reaching out to potentially unreliable sources such as unlicensed online pharmacies or telehealth sites,

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed pounds.

Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.

Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in recent years.

A survey reveals 25% of adults are considering using weight loss drugs without a prescription, raising concerns about safety and health risks.

A recent study suggests that people taking the GLP-1 liraglutide experienced more bone loss than people who exercised during the same time period. However, the study also found that exercising while taking liraglutide and other GLP-s may help prevent bone loss.

F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some Ozempic-takers have tiny appetites and dine at unusual hours to avoid spells of nausea.

In July, the U.S. Food and Drug Administration warned that people are overdosing on compounded semaglutide injectable products.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.